The Centers for Medicare and Medicaid Services has decided not to proceed with a proposal to cover weight-loss drugs like Wegovy and Zepbound under Medicare and Medicaid. This decision impacts approximately 7.5 million beneficiaries who could have accessed these medications for obesity treatment. Both Novo Nordisk and Lilly's statements express disappointment, underscoring the importance of recognizing obesity as a serious chronic disease. The Biden Administration's efforts to include these drugs under Medicare Part D were halted, leading to concerns regarding patient access to effective obesity treatments.
Medicare and Medicaid will not cover weight-loss drugs like Wegovy and Zepbound, limiting access for nearly 7.5 million recipients needing treatment for obesity.
Novo Nordisk emphasized the need for CMS regulations to recognize obesity as a serious chronic disease, aligning with current medical science.
Lilly expressed disappointment in the MA-Part D rule, indicating it hinders patient access to necessary obesity treatments.
The Biden Administration's proposal aimed at expanding coverage was left unexplained, leaving many concerned about access to essential medications.
Collection
[
|
...
]